GLSI Stock — Greenwich Lifesciences Inc

Greenwich Lifesciences Inc (GLSI)

Updated October 16, 2026.

GLSI is a Stock. Total return is 191.0% over the past 6.1 years, 39.3 points ahead of SPY at 151.7%.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing cancer immunotherapies focused on HER2/neu-expressing cancers, particularly breast cancer; its lead candidate GP2 is in Phase III trials for preventing breast cancer recurrence, and it is also advancing GLSI-100 in earlier-stage trials. The company does not currently have an established distribution schedule. This security appeals primarily to investors with high risk tolerance interested in exposure to early-stage drug development and potential long-term capital appreciation rather than current income.

GLSI performance versus SPY

Price and return data through 2026-10-16.

Total return is 191.0% over the past 6.1 years, 39.3 points ahead of SPY at 151.7%. Over the past year its total return — price change plus distributions reinvested — is 49.7%. Its deepest 1-year drawdown was 61.9%.

GLSI key facts

Asset type

Stock

Asset class

Equity

Inception date

09/25/2020

Distribution frequency

None

Last close

$14.55 (as of 2026-10-16)

Market cap

$213,567,926

Average volume

107670.0

Beta

1.457

Payout ratio

0.0%

EPS

$-1.53

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GLSI risks and drawbacks

The deepest 1-year drawdown on record here is 61.9%.

Who may consider GLSI — and who may not

It is a weaker fit for investors who need monthly cash flow (GLSI does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GLSI

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions